Journal
HEMATOLOGY
Volume 28, Issue 1, Pages -Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/16078454.2023.2220220
Keywords
Myelodysplastic syndromes; leukemia; ph chromosome; BCR; ABL
Categories
Ask authors/readers for more resources
This article reports a rare case of de nove Philadelphia (Ph)-positive myelodysplastic syndromes (MDS) transforming into chronic myeloid leukemia (CML) and rapidly progressing to acute myeloid leukemia (AML). The patient experienced relapse during treatment and died subsequently. In addition, the clinical features and outcomes of another 16 adult cases of MDS with de nove Ph-positive were reviewed.
Myelodysplastic syndromes (MDS) refer to a set of clonal hematopoietic disorders with fusion transcript as disease progression. Breakpoint cluster region/abelson (BCR::ABL) fusion mostly occurs during the progressive phase from MDS to higher stages and acute leukemia transformation. Besides, it is extremely rare reported on the diagnosis of MDS. Here, the first case of transformation of de nove philadelphia (Ph)-positive MDS to chronic myeloid leukemia (CML) with rapid progression to acute myeloid leukemia (AML) was reported. Fluorescence in situ hybridization (FISH) analysis revealed an atypical BCR::ABL positive signal (2R2G1Y) that accounted for 3% at the diagnosis of MDS and increased to 21.4% at information to CML. The result of multiplex reverse transcriptase polymerase chain reaction (RT-PCR) indicated a rearrangement of e19a2 (p230 BCR::ABL). The treatment with 400 mg of imatinib daily at the transformation from MDS to CML led to a hematological response. However, the patient stopped taking imatinib due to the worsening of cytopenias after five weeks of therapy and rapid progression to AML in another two months. The treatment with azacitidine (AZA) and venetoclax (VEN) achieved partial remission (PR). Unfortunately, the patient relapsed six months after PR and died shortly thereafter. In addition, another 16 cases of adult cases that reported MDS with de nove Ph-positive were also reviewed to learn about clinical features and outcomes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available